Global clinical trials activity decreased by 11.7% in Q1 2020, when compared with the same quarter in 2019, according to GlobalData.
Industry-sponsored trials accounted for a 42.3% share of overall activity in Q1 2020, an increase of 1.4% when compared with Q1 2019.
Go deeper with GlobalData
Non-industry-sponsored trials accounted for a 57.7% share of all clinical trials in Q1 2020, marking a decrease of 1.4% when compared with the same period in 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Q1 2020 industry-sponsored clinical trials activity by therapy areas
Oncology was the leading therapy area for industry-sponsored clinical trials in Q1 2020, accounting for a 28.3% share of all trials.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThis was followed by infectious disease with a 15.4% share, central nervous system with 13.0%, respiratory with 9.9% and metabolic disorders with 7.8%.
In Q1 2019, oncology led with a 27.1% share, followed by central nervous system with 15.3%, infectious disease with 11.1%, metabolic disorders with 9.3%, and cardiovascular with 7.8%.
| Industry-sponsored trials: Q1 2020 vs Q1 2019 | |||
|---|---|---|---|
| Therapy Area | Q1 2019 | Q1 2020 | Activity |
| Oncology | 27.1% | 28.3% |  |
| Infectious Disease | 11.1% | 15.4% | |
| Central Nervous System | 15.3% | 13.0% |  |
| Respiratory | 6.5% | 9.9% | |
| Metabolic Disorders | 9.3% | 7.8% | |
| Cardiovascular | 7.8% | 7.1% | |
| Gastrointestinal | 6.8% | 6.6% | |
| Immunology | 6.4% | 4.9% | |
| Dermatology | 6.0% | 4.1% | |
| Hematological Disorders | 3.1% | 3.7% | |
| Musculoskeletal Disorders | 4.1% | 3.5% | |
| Ophthalmology | 2.7% | 3.2% | |
| Genito Urinary System And Sex Hormones | 3.0% | 2.3% | |
| Women’s Health | 2.2% | 2.1% | |
| Genetic Disorders | 1.7% | 1.5% | |
| Ear Nose Throat Disorders | 2.2% | 1.4% | |
| Mouth and Dental Disorders | 0.4% | 0.7% | |
| Hormonal Disorders | 0.8% | 0.5% | |
| Male Health | 0.9% | 0.4% | |
| Nutritional Disorders | 0.6% | 0.4% | |
| Non Malignant Disorders | 0.3% | 0.0% | |
Most active therapy areas in non-industry-sponsored clinical trials
In Q1 2020 the leading therapy area for non-industry-sponsored clinical trials was central nervous system, accounting for a 21.9% share of all trials.
This was followed infectious disease with a 19.5% share, oncology with 19.3%, respiratory with 12.8%, and cardiovascular with 8.9%.
In Q1 2019, central nervous system held the lead in non-industry-sponsored clinical trials with a 27.1% share, followed by oncology with 19.3%, cardiovascular with 9.5%, gastrointestinal with 8.5%, and metabolic disorders with 8.3%.
| Non-Industry-sponsored trials: Q1 2020 vs Q1 2019 | |||
|---|---|---|---|
| Therapy Area | Q1 2019 | Q1 2020 | Activity |
| Central Nervous System | 27.1% | 21.9% | |
| Infectious Disease | 7.7% | 19.5% | |
| Oncology | 19.3% | 19.3% | |
| Respiratory | 4.1% | 12.8% | |
| Cardiovascular | 9.5% | 8.9% | |
| Gastrointestinal | 8.5% | 6.5% | |
| Metabolic Disorders | 8.3% | 5.5% | |
| Women’s Health | 6.2% | 5.1% | |
| Musculoskeletal Disorders | 5.8% | 5.0% | |
| Dermatology | 3.1% | 3.0% | |
| Immunology | 3.5% | 3.0% | |
| Genito Urinary System And Sex Hormones | 3.6% | 2.6% | |
| Hematological Disorders | 3.7% | 2.6% | |
| Mouth and Dental Disorders | 3.2% | 2.3% | |
| Ophthalmology | 1.6% | 1.7% | |
| Ear Nose Throat Disorders | 1.1% | 1.4% | |
| Nutritional Disorders | 1.1% | 0.9% | |
| Hormonal Disorders | 0.9% | 0.6% | |
| Male Health | 0.6% | 0.6% | |
| Genetic Disorders | 0.8% | 0.4% | |
| Non Malignant Disorders | 0.4% | 0.3% | |
Asia-Pacific region has the most activity for industry-sponsored clinical trials
Asia-Pacific was the most active region for industry-sponsored clinical trials activity in Q1 2020 with a 48.0% share, compared with 51.3% in Q1 2019.
North America was the second most active region with a 36.0% share in Q1 2020, up from 32.5% in Q1 2019, followed by Europe with a 29.2% share in Q1 2020, down from 30.5% in Q1 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 83.8% share in industry-sponsored clinical trials in Q1 2020, compared with 84.0% in Q1 2019. Multinational trials accounted for 16.2% in Q1 2020, against 16.0% in Q1 2019.
Regional activity for non-industry-sponsored clinical trials
Asia-Pacific saw the most non-industry-sponsored clinical trial activity in Q1 2020 with a 53.0% share, up from 52.6% in Q1 2019.
North America held the second position with a 17.2% share in Q1 2020, compared with 15.7% in Q1 2019. This was followed by Europe with a 15.2% share in Q1 2020, as against 14.6% in Q1 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies accounted for 98.9% share of non-industry-sponsored clinical trials in Q1 2020, compared with 98.2% in Q1 2019. Multinational trials accounted for a 1.1% share in Q1 2020, down from 1.8% in Q1 2019.
Clinical trials by phase in Q1 2020
Phase II trials outnumbered all other studies with a 38.8% share for industry-sponsored trials in Q1 2020, compared with 35.2% in Q1 2019.
The share of Phase I trials stood at 30.2% in Q1 2020, down from 37.2% in Q1 2019. Phase III trials increased to 17.8% in Q1 2020, compared with 14.9% in Q1 2019, followed by Phase IV trials with a 13.3% share in Q1 2020, against 12.8% in Q1 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
For non-industry-sponsored clinical trials, Phase II activity decreased to a 41.9% share in Q1 2020, compared with 52.4% in Q1 2019.
Phase IV trials were the second most active with a 20.6% share in Q1 2020, compared with 19.0% in Q1 2019. Phase I trials held a 19.1% share in Q1 2020, against 11.2% in Q1 2019, followed by Phase III trials with an 18.5% share in Q1 2020, over 17.4% in Q1 2019.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
